These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27919352)

  • 41. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
    Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Lemelin V; Lamarche B; Couture P
    J Lipid Res; 2018 Aug; 59(8):1501-1509. PubMed ID: 29946054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
    Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ
    Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
    Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
    Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Michishita I
    J Atheroscler Thromb; 2016 Jul; 23(7):848-56. PubMed ID: 26797266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
    Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels.
    Hansel B; Bonnefont-Rousselot D; Orsoni A; Bittar R; Giral P; Roussel R; Marre M; Mohammedi K; Bruckert E; Chapman MJ; Kontush A
    J Clin Lipidol; 2016; 10(5):1172-81. PubMed ID: 27678434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
    Panahi Y; Ghahrodi MS; Jamshir M; Safarpour MA; Bianconi V; Pirro M; Farahani MM; Sahebkar A
    Clin Biochem; 2019 Dec; 74():12-18. PubMed ID: 31493378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.
    Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J
    Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ; Lambert G; Dahlbäck B; Nielsen LB; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.